Table 2.
Description of the resolved PDRP with the pharmaceutical care programme
| Categories of PDRP* | N (%) |
| Health problem insufficiently treated | 39 (47.6) |
| Inappropriate dose, dosage schedule and/or duration | 24 (29.3) |
| Interactions | 6 (7.3) |
| Duplicity | 3 (3.7) |
| Wrongly administered drug | 1 (1.2) |
| Other | 9 (11.0) |
| ATC Group of the active ingredient involved in the resolved PDRP | |
| A (Alimentary tract and metabolism) | 10 (12.2) |
| B (Blood and blood-forming organs) | 7 (8.5) |
| C (Cardiovascular system) | 27 (32.9) |
| C/G (Cardiovascular system)/(Genitourinary system and sex hormones) | 1 (1.2) |
| G (Genitourinary system and sex hormones) | 3 (3.7) |
| J (Anti-infective agents for systemic use) | 5 (6.1) |
| B/J (Blood and blood-forming organs)/(Anti-infective agents for systemic use) | 4 (4.9) |
| L (Antineoplastic and immunomodulating agents) | 3 (3.7) |
| M (Musculoskeletal system) | 3 (3.7) |
| N (Nervous system) | 6 (7.3) |
| R (Respiratory system) | 6 (7.3) |
| S (Sensory organs) | 4 (4.9) |
| V (Various) | 3 (3.7) |
| Procedures followed to detect PDRP | |
| Elaboration and record DTC/medication reconciliation (admission) | 37 (45.1) |
| Medication reconciliation (discharge)/supplying information (discharge) | 17 (20.7) |
| Physician prescription validation/patient follow-up | 28 (34.1) |
*PDRP according to the Third Consensus of Granada 17 classification (n=82).
DTC, drug treatment chart; PDRP, potential drug-related problem.